Clinical Neurology and Neurosurgery
Volume 112, Issue 4 , Pages 320-323 , May 2010

The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients

  • Lan Tan

      Affiliations

    • Department of Neurology, Qingdao Municipal Hospital, School of Medicine, Qingdao University, No.5 Donghai Middle Road, Qingdao, Shandong Province 266071, China
    • Department of Neurology, Qingdao Municipal Hospital, School of Medicine and Pharmaceutics, Ocean University of China, 266071, China
    • Corresponding Author InformationCorresponding author at: Department of Neurology, Qingdao Municipal Hospital, School of Medicine, Qingdao University, No.5 Donghai Middle Road, Qingdao, Shandong Province 266071, China. Tel.: +86 532 8890 5659; fax: +86 532 85968434.
    • ,
  • Jin-Tai Yu

      Affiliations

    • Department of Neurology, Qingdao Municipal Hospital, School of Medicine, Qingdao University, No.5 Donghai Middle Road, Qingdao, Shandong Province 266071, China
    • Department of Neurology, Qingdao Municipal Hospital, School of Medicine and Pharmaceutics, Ocean University of China, 266071, China
    • ,
  • Yan-Ping Sun

      Affiliations

    • Department of Neurology, the Affiliated Hospital of the Medical College of Qingdao University, Qingdao 266003, Shandong Province, China
    • ,
  • Jiang-Rong Ou

      Affiliations

    • Department of Neurology, Qingdao Municipal Hospital, School of Medicine, Qingdao University, No.5 Donghai Middle Road, Qingdao, Shandong Province 266071, China
    • Department of Neurology, Qingdao Municipal Hospital, School of Medicine and Pharmaceutics, Ocean University of China, 266071, China
    • ,
  • Jing-Hui Song

      Affiliations

    • Department of Neurology, the Affiliated Hospital of the Medical College of Qingdao University, Qingdao 266003, Shandong Province, China
    • ,
  • Yang Yu

      Affiliations

    • Department of Neurology, the Affiliated Hospital of the Medical College of Qingdao University, Qingdao 266003, Shandong Province, China

Received 15 April 2009 ,Revised 10 November 2009 ,Accepted 5 January 2010.

References 

  1. Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med. 2004;10:685–692
  2. Shorvon S. Handbook of epilepsy treatment. second ed.. Oxford: Blackwell; 2005;
  3. Klotz U. The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications. Clin Pharmacokinet. 2007;46:271–279
  4. Davis R, Peters DH, McTavish D. Valproic acid: a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs. 1994;47:332–372
  5. Anari MR, Burton RW, Gopaul S, Abbott FS. Metabolic profiling of valproic acid by cDNA-expressed human cytochrome P450 enzymes using negative-ion chemical ionization gas chromatography-mass spectrometry. J Chromatogr B. 2000;742:217–227
  6. Kiang TK, Ho PC, Anari MR, Tong V, Abbott FS, Chang TK. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype. Toxicol Sci. 2006;94:261–271
  7. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007;116:496–526
  8. Nakajima M, Fukami T, Yamanaka H, Higashi E, Sakai H, Yoshida R, et al. Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther. 2006;80:282–297
  9. Nakajima M, Komagata S, Fujiki Y, Kanada Y, Ebi H, Itoh K, et al. Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. Pharmacogenet Genomics. 2007;17:431–445
  10. Crettol S, Déglon JJ, Besson J, Croquette-Krokkar M, Gothuey I, Hämmig R, et al. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther. 2005;78:593–604
  11. Tsuchiya K, Gatanaga H, Tachikawa N, Teruya K, Kikuchi Y, Yoshino M, et al. Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun. 2004;319:1322–1326
  12. Kirchheiner J, Brockmöller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther. 2005;77:1–16
  13. Ho PC, Abbott FS, Zanger UM, Chang TK. Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes. Pharmacogenomics J. 2003;3:335–342
  14. Ciulla TA, Sklar RM, Hauser SL. A simple method for DNA purification from peripheral blood. Anal Biochem. 1988;174:485–488
  15. Oscarson M, McLellan RA, Gullstén H, Yue QY, Lang MA, Bernal ML, et al. PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett. 1999;448:105–110
  16. Lang T, Klein K, Fischer J, Nüssler AK, Neuhaus P, Hofmann U, et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics. 2001;11:399–415
  17. Yasar U, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjöqvist F. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun. 1999;254:628–631
  18. Yu BN, Luo CH, Wang D, Wang A, Li Z, Zhang W, et al. CYP2C9 allele variants in Chinese hypertension patients and healthy controls. Clin Chim Acta. 2004;348:57–61
  19. Guan S, Huang M, Li X, Chen X, Chan E, Zhou SF. Intra- and inter-ethnic differences in the allele frequencies of cytochrome P450 2B6 gene in Chinese. Pharm Res. 2006;23:1983–1990
  20. Terwilliger JD, Ott J. Handbook of human genetic linkage. New York: John Hopkins Univ. Press; 1994;
  21. Xie HJ, Yasar U, Lundgren S, Griskevicius L, Terelius Y, Hassan M, et al. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J. 2003;3:53–61
  22. Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE. Allele variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys. 1996;333:447–458
  23. Hannu R, Arja R, Harriet G, Olavi P. Polymorphisms of CYP2A6 and its practical consequences. Br J Clin Pharmacol. 2001;52:357–363
  24. Hiratsuka M, Takekuma Y, Endo N, Narahara K, Hamdy SI, Kishikawa Y, et al. Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur J Clin Pharmacol. 2002;58:417–421
  25. Sipeky C, Lakner L, Szabo M, Takacs I, Tamasi V, Polgar N, et al. Interethnic differences of CYP2C9 alleles in healthy Hungarian and Roma population samples: relationship to worldwide allelic frequencies. Blood Cells Mol Dis. 2009;43:239–242
  26. Devane CL. Pharmacokinetics, drug interactions, and tolerability of valproate. Psychopharmacol Bull. 2003;37:25–42

PII: S0303-8467(10)00007-7

doi: 10.1016/j.clineuro.2010.01.002

Clinical Neurology and Neurosurgery
Volume 112, Issue 4 , Pages 320-323 , May 2010

Article Tools